English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 25 March 2019, 18:00 HKT/SGT
Share:
    

Source: Novotech
Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk

SYDNEY, Mar 25, 2019 - (ACN Newswire) - Clinical Network Services (CNS) USA, an integrated services group focused on clinical product development and subsidiary of Asia-Pacific specialist CRO Novotech, today announced the appointment of Dr Robert Malone as Principal Consultant in its Washington D.C. office. CNS is headquartered in Australia with offices in New Zealand, the UK and the USA.

Dr Robert Malone, Principal Consultant at the CNS BioDesk, Washington D.C.

Dr Malone brings more than 20 years of management and leadership experience in academia, pharmaceuticals and biotechnology, with deep expertise in regulatory and medical strategy for global clinical product development. Dr Malone is an internationally recognised physician and scientist for his work in clinical trials in the areas of vaccines, gene therapy, biodefense and immunology, and specifically as one of the original inventors of DNA vaccination and multiple non-viral gene therapy technologies (RNA and DNA).

Commenting on the new role, Robert said: "I am delighted to join the CNS BioDesk USA consulting team; this is an exciting opportunity to work within a highly professional and experienced group that is dedicated to adding value to clients' early phase programs and their US regulatory strategies."

Russell Neal, CNS Managing Director said: "Dr Malone brings a wealth of industry and consulting experience to our US BioDesk team, and his appointment reflects CNS' ongoing commitment to the continuous growth and evolution of BioDesk to service CNS' international clients as they navigate US and global regulatory strategies."

CNS' BioDesk division is an intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval. It is a uniquely internationally experienced team with particular expertise in the areas of vaccines, oncology, infectious disease as well as cell and gene therapies.

CNS and Novotech, the largest Asia-Pacific-based CRO, merged in late 2018 as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials.

About Clinical Network Services
Clinical Network Services (CNS) is an integrated services group focused on product development based in Australia with offices in New Zealand, the UK and the USA, which creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials and the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with a committed, highly experienced Australian/New Zealand clinical services and biometrics team. More about CNS and its intelligent development services at www.clinical.net.au

About BioDesk
CNS' BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. More about BioDesk services can be found at www.cnsbiodesk.com

About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. For more, see www.novotech-cro.com.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

Media Contact:
communications@novotech-cro.com
Susan Fitzpatrick-Napier, AU: +61 2 8218 2144
USA: +1 415 951 3228, Asia: +65 3159 3427


Topic: Press release summary
Source: Novotech

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Novotech Releated News
Sept 28, 2020 14:00 HKT/SGT
노보텍 (Novotech), 파마 인텔리전스 (Pharma Intelligence)의 사이트라인 어워드 2020 (Citeline Awards 2020) 최종후보로 선정
Sept 9, 2020 12:00 HKT/SGT
노보텍 (Novotech), 식품의약품안전처 (MFDS) 임상시험 승인 상위 임상시험수탁기관 (CRO) 진입
Sept 1, 2020 09:00 HKT/SGT
아시아 태평양 지역 임상시험수탁기관 (CRO) 리더 노보텍 (Novotech), ‘2020년 프로스트 & 설리번 올해의 아시아-태평양 지역 임상시험수탁기관’ 상 수상
Aug 27, 2020 14:00 HKT/SGT
Novotech 作为亚太地区 CRO 领军者–荣膺“Frost & Sullivan 亚太地区合同研究组织(CRO)2020 年度企业”称号
Aug 27, 2020 14:00 HKT/SGT
Novotech 作為亞太地區 CRO 領軍者–榮膺“Frost & Sullivan 亞太地區合同研究組織(CRO)2020 年度企業”稱號
More news >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575